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Background and purpose: The introduction of ﬂuorescence-based techniques, and in particular the development of ﬂuores-
cent ligands, has allowed the study of G protein-coupled receptor pharmacology at the single cell and single molecule level.
This study evaluated how the physicochemical nature of the linker and the ﬂuorophore affected the pharmacological properties
of ﬂuorescent agonists and antagonists.
Experimental approach: Chinese hamster ovary cells stably expressing the human adenosine A1 receptor and a cyclic 3′,5′
adenosine monophosphate response element-secreted placental alkaline phosphatase (CRE-SPAP) reporter gene, together with
whole cell [3H]-8-cyclopentyl-1,3-dipropylxanthine (DPCPX) radioligand binding, were used to evaluate the pharmacological
properties of a range of ﬂuorescent ligands based on the antagonist xanthine amine congener (XAC) and the agonist 5′
(N-ethylcarboxamido) adenosine (NECA).
Key results: Derivatives of NECA and XAC with different ﬂuorophores, but equivalent linker length, showed signiﬁcant
differences in their binding properties to the adenosine A1 receptor. The BODIPY 630/650 derivatives had the highest afﬁnity.
Linker length also affected the pharmacological properties, depending on the ﬂuorophore used. Particularly in ﬂuorescent
agonists, higher agonist potency could be achieved with large or small linkers for dansyl and BODIPY 630/650 derivatives,
respectively.
Conclusions and implications: The pharmacology of a ﬂuorescent ligand was critically inﬂuenced by both the ﬂuorophore
and the associated linker. Furthermore, our data strongly suggest that the physicochemical properties of the ﬂuorophore/linker
pairing determine where in the environment of the target receptor the ﬂuorophore is placed, and this, together with the
environmental sensitivity of the resulting ﬂuorescence, may ﬁnally decide its utility as a ﬂuorescent probe.
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Adenosine A1 receptors are G protein-coupled receptors
(GPCRs) that signal via Gi/o proteins to inhibit adenylyl cyclase
activity and reduce the cellular levels of the second messenger,
cyclic 3′,5′ adenosine monophosphate (cyclic AMP; Libert
et al., 1992; Olah and Styles, 1995; Fredholm et al., 2001). Our
current understanding of the molecular pharmacology of the
adenosine A1-receptor has been deduced primarily from the
use of radioligand binding techniques for studying ligand-
receptor interactions and the measurement of intracellular
second messenger generation. These experiments require large
numbers of cells, and the pharmacological parameters that are
deduced from them therefore represent the average for the cell
population. However, it is now evident that adenosine A1
receptors are not uniformly distributed in the plasma mem-
brane of individual cells but instead are located within mem-
brane compartments and microdomains (Gines et al., 2001;
Zajchowshi and Robbins, 2002; Helmreich, 2003). The intro-
ductionofﬂuorescence-basedtechniques,andinparticularthe
development of ﬂuorescent ligands, has now advanced the
study of GPCR pharmacology to the single-cell and single
molecule level (Emmerson et al., 1997; Harikumar et al., 2002;
Baker et al., 2003; Briddon et al., 2004; Cordeaux et al., 2008;
Daly and McGrath, 2003). For example, the application of
techniquessuchasﬂuorescencecorrelationspectroscopy(FCS)
has provided the means by which the diffusion of receptor
specieswithindeﬁnedmembranemicrodomainscanbymoni-
tored in real time (Briddon and Hill, 2007), and we have used
both ﬂuorescent agonists and antagonists to study the adenos-
ine A1 receptor using this technique (Briddon et al., 2004;
Middleton et al., 2007).
The general approach to the design of a ﬂuorescent ligand
has been to take a parent molecule with known pharmaco-
logical properties and to add a ﬂuorophore to it. Given the
size of most ﬂuorophores in relation to the active parent
molecule, it would not be surprising to observe that this
process may result in alterations to the pharmacology of the
parent molecule (Baker et al., 2003; Middleton and Kellam,
2005; Middleton et al., 2007). An ideal ﬂuorescent molecule
would retain the properties of the parent ligand. For an
antagonist, this would mean retaining high afﬁnity and selec-
tivity for the receptor under study, as well as the neutral
antagonist or inverse agonist properties of the parent ligand.
For an agonist, the ﬂuorescent molecule must retain the efﬁ-
cacy of the parent ligand, and enough potency still to be
pharmacologically useful. However, the addition of a ﬂuoro-
phore to a known ligand clearly alters its structure, and the
pharmacology of the subsequent molecule needs to be care-
fully studied in order to determine its usefulness (Briddon
et al., 2004; Middleton and Kellam, 2005; Cordeaux et al.,
2008).
We have designed and synthesized a number of ﬂuorescent
agonist and antagonist probes of the human adenosine A1
receptor, which vary in both their ﬂuorescent label and also
in the composition and length of the linker that attaches
the ﬂuorophore to the parent molecule. Our aim was to
investigate the effect of these variations on the pharmacol-
ogy of these probes, and also their usefulness as A1 receptor
probes in live cell imaging. Here, we show that the nature of
both the linker and the ﬂuorophore can exert major effects
on the pharmacological properties of both agonists and
antagonists.
Methods
Cell culture
Chinese hamster ovary (CHO) cells stably expressing both the
human A1-adenosine receptor and a cyclic AMP response
element-secreted placental alkaline phosphatase (CRE-SPAP)
reporter gene were used throughout this study (CHO-A1;
Baker and Hill, 2007). Cells were grown in Dulbecco’s modi-
ﬁed Eagle’s medium/nutrient mix F12 (DMEM/F12) contain-
ing 10% fetal calf serum and 2 mM L-glutamine in a
humidiﬁed 5% CO2: 95% air atmosphere at 37°C.
Synthesis of the ﬂuorescent ligands
The chemical structures of all the compounds assessed in
these experiments are shown in Figures 1 and 2. The synthesis
of compounds (1)–(4) has been previously described (Middle-
ton et al., 2007). Compound (5) was synthesized in an iden-
tical manner to that of (1)–(4), except the linker was installed
using N
1-benzyloxycarbonyl-1,8-diamino-3,6-dioxooctane.
Compounds (6), (7) and (8) were synthesized in an identical
manner to (2) via the key intermediate N
6-(4-aminobutyl)-
5′-ethylamino-5′-oxo-5′-deoxyadenosine (Middleton et al.,
2007), except the ﬂuorophores coupled to this inter-
mediate were 4,4-diﬂuoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-
indacene-3-propionic acid, succinimidyl ester (BODIPY FL SE,
Invitrogen, Carlsbad, CA, USA) for (6) and dansyl chloride for
(7), respectively. Compound (8) was synthesized in an iden-
tical manner to (2), except the modiﬁed ﬂuorophore,
N-dansyl-8-aminooctanoic acid was coupled to N
6-(4-
aminobutyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine using
1,1′-carbonyldiimidazole (CDI) in N,N-dimethylformamide
(DMF). Compound (9) was synthesized in an identical
manner to (2), except the terminal ﬂuorophore was
coupled using 6-((4,4-diﬂuoro-5,7-dimethyl-4-bora-3a,4a-
diaza-s-indacene-3-propionyl)amino)hexanoic acid, succin-
imidyl ester (BODIPY FL-X, SE). Compound (10) was
synthesized in an identical manner to (7), except the linker
was installed using N
1-benzyloxycarbonyl-1,11-diaminound
ecane. Compounds (11), (12) and (13) were all synthesized
via the key intermediate N
6-(4-aminobutyl)-5′-
ethylamino-5′-oxo-5′-deoxyadenosine (Middleton et al.,
2007), except the ﬂuorophores coupled to this intermediate
were Texas Red-X, succinimidyl ester (Invitrogen), Cy5
monosuccinimidyl ester (GE Healthcare, Little Chalfont,
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Figure 1 Chemical structures of ﬂuorescent NECA derivatives. ABEA, N6-(4-aminobutyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; ADOEA,
N6-(8-amino-3,6-dioxaoctyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; AO, 8-aminooctanoyl; AOEA, N6-(8-aminooctyl)-5′-ethylamino-5′-oxo-
5′-deoxyadenosine; APEA, N
6-(5-aminopentyl)- 5′-ethylamino-5′-oxo-5′-deoxyadenosine; APrEA, N6-(3-aminopropyl)-5′-ethylamino-5′-oxo-5′-
deoxyadenosine; AUEA, N6-(11-aminoundecyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; X, 6-aminohexanoyl.
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(Novabiochem, Nottingham, UK), respectively. Compound
(14) has been previously described (Briddon et al., 2004).
Compounds (15), (16), (18) and (19) were synthesized in an
identical manner to (14), except the ﬂuorophores coupled to
xanthine amine congener (XAC) were Texas Red-X succinim-
idyl ester (Invitrogen), Cy5 monosuccinimidyl ester (GE
Healthcare), EVOBlue 30 succinimidyl ester (Novabiochem)
and dansyl chloride, respectively. Compound (17) was pre-
pared by reacting XAC and suberic acid monomethyl ester in
DMF in the presence of CDI. The crude 7-carboxyheptanoyl-
XAC methyl ester product was saponiﬁed and reacted with
4,4-diﬂuoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-
propionyl ethylenediamine, hydrochloride (BODIPY FL EDA,
Invitrogen) using CDI as the coupling reagent in DMF.
Compound (20) was synthesized by coupling XAC with N-
dansyl-8-aminooctanoic acid using 1,1′-carbonyldiimidazole
in DMF. Compound (21) was synthesized by reacting
N-
tbutyloxycarbonylaminocaproic acid with XAC using dicy-
clohexylcarbodiimide (DCC) as the coupling reagent in DMF.
Following acidolytic removal of the
tbutyloxycarbonyl
protecting group, aminocaproyl-XAC was coupled with
N-dansyl-6-aminohexanoic acid using diisopropylcarbodiim-
ide as the coupling reagent in DMF. All compounds were
puriﬁed using preparative thin-layer chromatography (pTLC),
as previously described (Briddon et al., 2004; Middleton et al.,
2007). Single peak purity of all compounds was conﬁrmed by
analytical reversed-phase high-performance liquid chroma-
tography (recorded on a Waters Millennium 995 LC system,
Milford, MA, USA) and the structures conﬁrmed using high-
resolution mass spectrometry (recorded on a Waters 2795
Separation Module/Micromass LCT platform).
[
3H]-8-cyclopentyl-1,3-dipropylxanthine (DPCPX)
whole cell binding
CHO-A1 cells were grown to conﬂuence over 24 h in white-
sided 96 well view plates. The following day, the media was
removed and replaced with 100 mL serum-free media (i.e.
DMEM/F12 containing 2 mM L-glutamine only) containing
the competing ligand. This was immediately followed by the
addition of 100 mL serum-free media containing
3H-DPCPX
(to give a ﬁnal concentration of
3H-DPCPX of 0.99–1.77 nM).
Total and non-speciﬁc binding (as deﬁned by 10 mM XAC)
were measured in each experiment. Cells were then incu-
bated for 2 h at 37°C in a humidiﬁed 5% CO2: 95% room air
atmosphere. After 2 h, the media and drugs were removed,
and the cells washed twice by the addition and removal of
phosphate-buffered saline at 4°C (2 ¥ 200 mL per well). A
white base was then added to the plate, followed by 100 mL
Microscint 20 (Perkin Elmer, Shelton, CT, USA) per well and
a sealant ﬁlm placed over the wells. The plates were then
counted the following day on a Topcount (Perkin Elmer) for
2 min per well.
CRE-SPAP gene transcription
Cells were grown to conﬂuence in 96-well plates in 100 mL
DMEM/F12 containing 10% fetal calf serum and 2 mM
L-glutamine. Once conﬂuent, the media was removed and
replaced with 100 mL serum-free media (DMEM/F12 contain-
ing 2 mM L-glutamine), and the cells incubated for a further
24 h. Where used, Pertussis toxin (PTX, 100 ng·mL
–1) was
added for this 24 h period. On the day of experimentation,
the serum-free media was removed and replaced with 100 mL
serum-free media  antagonist at the ﬁnal required concen-
tration, and the cells incubated for 1 h at 37°C (5% CO2).
Agonists (10 mL, diluted in serum free media) were then
added to each well, and the plate incubated at 37°C for
10 min. Forskolin (10 mL) was then added to all but the basal
wells, and the cells incubated for a further 5 h at 37°C (5%
CO2). After 5 h, the media and drugs were removed, 40 mL
serum-free media was added to each well, and the cells incu-
bated for a further 1 h at 37°C. The plates were then incu-
bated at 65°C for 30 min to destroy any endogenous
phosphatases before the plates were then cooled to 37°C.
4-nitrophenyl phosphate (pNPP; 100 mL of 5 mM) in dietha-
nolamine buffer was added to each well, and the plates incu-
bated at 37°C until the yellow colour developed. The plates
were then read on a Dynex MRX plate reader (Chelmsford,
MA, USA) at 405 nm.
Confocal microscopy
Cells were grown to 100% conﬂuency in Labtek 8-well
chambered-coverglasses (Nalgene Nunc International, Scien-
tiﬁc Laboratory Supplies, Nottingham, UK) in 400 mL DMEM-
F12 media containing 10% FCS and 2 mM glutamine. The
media was replaced with 400 mL N-2-Hydroxyethylpiperazine-
N′-2-ethanesulfonic acid (HEPES)-buffered saline (HBS,
Briddon et al., 2004) at room temperature. Confocal micros-
copy was performed using a Zeiss LSM510 laser-scanning
microscope using either a Zeiss 40 ¥ 1.3NA oil-immersion lens
(Zeiss, Jena, Germany) or (for experiments using 364 nm exci-
tation) a C-Apochromat 60 ¥ 1.2NA water-immersion lens.
Images of ligands were captured using the following optical
conﬁgurations: BODIPY 630/650, Cy5 and EVOBlue 30 con-
jugates, 633 nm excitation, with emission captured through a
650LP ﬁlter; Texas Red conjugates, 543 nm excitation and
560LP emission ﬁlter; BODIPY-FL conjugates, 488 nm excita-
tion and LP505 emission and dansyl conjugates 364 nm exci-
tation and 475-525BP emission. In each case, a pinhole
diameter of 1 Airy unit was used.
Initial images were captured in the absence of ligand to
determine the level of auto-ﬂuorescence under each excita-
tion wavelength, and settings adjusted to minimize this.
Single equatorial images were subsequently captured follow-
ing a 5 min incubation of the indicated concentration of
ﬂuorescent ligands (in HBS). If membrane ﬂuorescence was
seen, the media and ﬂuorescent drug were removed from the
well and the cells washed by the addition and removal of
400 mL HBS. A further 400 mL HBS was added, and a further
image captured. This was to ensure that any apparent
membrane-localized ﬂuorescence was indeed bound to the
membrane and not just due to ﬂuorescent ligand present in
the media between cells. For any given experimental condi-
tion, a minimum of three different cell preparations on three
different days with different drug dilutions were used. In the
text, ‘n’ refers to the number of different complete experi-
ments performed.
Fluorescent A1 receptor ligands
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Ligand solutions were prepared in methanol or HBS (1 mM for
XAC-X-BY630 and XAC-X-TR; 50 mM for XAC-dansyl). Exci-
tation and emission spectra (2 nm intervals) were collected
using a Flexstation 96-well ﬂuorescence plate reader (Molecu-
lar Devices Corporation, Sunnyvale, CA, USA) using 100 mLo f
ligand dispensed in to UV-transparent ﬂat-bottomed 96-well
plates (Costar, Fisher Scientiﬁc, Loughborough, UK). Data
analysis was performed in Softmax Pro 4.2 (Molecular Devices
Corporation) and GraphPad Prism 4.0 (GraphPad, San Diego,
CA, USA).
Data analysis
3H-DPCPX whole cell binding. Curves for inhibition of speciﬁc
binding of
3H-DPCPX by a range of concentrations of 5′
(N-ethylcarboxamido)adenosine (NECA), XAC and the ﬂuo-
rescent adenosine A1 receptor ligands were ﬁtted to the
following equation:
% of specific binding
A
AI C
=−
×[]
[] +
100
100
50
where [A] is the concentration of competing ligand, and IC50
is the concentration that inhibits speciﬁc binding by 50%.
Antagonist dissociation constants (KB) were then determined
from the following expression:
K
IC K
KL
B
D
D
=
×
+[]
50
where [L] and KD are the concentration and dissociation con-
stant of
3H-DPCPX, respectively. The KD value of
3H-DPCPX
was previously determined in this cell line to be 3.61 nM
(Baker and Hill, 2007).
Functional experiments
One-site concentration responses curves. Sigmoidal agonist
concentration-response curves were ﬁtted to the data using
the following equation through computer-assisted non-linear
regression using the programme GraphPad Prism 2:
Response
EA
EC A
=
×[]
+[]
MAX
50
where EMAX is the maximal response, [A] is the agonist con-
centration and EC50 (or IC50) is the concentration of agonist
that produces 50% of the maximal response.
Antagonist KD values were then calculated from the shift of
the agonist concentration responses in the presence of a ﬁxed
concentration of antagonist using the following equation:
DR
B
K
=+
[]
1
D
where DR (dose ratio) is the ratio of the agonist concentration
required to stimulate an identical response in the presence
and absence of a ﬁxed concentration of antagonist [B].
Two-site agonist curves. As many concentration response
curves clearly contained two components, two-site analysis
was required for most ligands. This was performed using the
following equation:
Response Basal FK Basal
A
AI C
S
A
A
=+ − () −
[]
[] + ()
⎡
⎣ ⎢
⎤
⎦ ⎥
+
[]
[] +
1
50
MAX
E EC50 ()
⎡
⎣ ⎢
⎤
⎦ ⎥
where basal is the response in the absence of agonist, FK is the
response to a ﬁxed concentration of forskolin, [A] is the con-
centration of A1-receptor agonist, IC50 is the concentration of
agonist that inhibits 50% of the response to forskolin, SMAX is
the maximum stimulation of the Gs-component of the
response to the agonist and EC50 is the concentration of
agonist that stimulates a half maximal Gs-response.
A maximal forskolin concentration (3 mM) was included in
each CRE-gene transcription plate for each separate experi-
ment. All data are presented as mean  SEM of triplicate
determinations, and n in the text refers to the number of
separate experiments.
Materials
CGS 15943, DPCPX and NECA were from Tocris Cookson
(Avonmouth, Bristol, UK).
3H-DPCPX was obtained from
Amersham International (Buckinghamshire, UK). Fetal calf
serum was from PAA laboratories (Teddington, Middlesex,
UK). XAC was from Sigma Chemicals (Poole, Dorset, UK),
who also supplied all other reagents. Pertussis toxin was from
Calbiochem, Nottingham, UK. The receptor nomenclature
used in this manuscript follows Alexander et al. (2008).
Results
In order to systematically test the effect of ﬂuorophore, linker
length and composition on ligand pharmacology, we synthe-
sized a number of ﬂuorescent derivatives of the archetypal
adenosine A1-receptor agonist, NECA and the corresponding
antagonist, XAC (Figures 1 and 2, Table 1; compounds 1–21).
We have previously demonstrated the use of the red-excited
ﬂuorophore BODIPY 630/650 to generate functional ﬂuores-
cent A1-receptor agonists and antagonists (Briddon et al.,
2004; Middleton et al., 2007). We have extended the range of
red-emitting ﬂuorophores tested to include the cyanine dye,
Cy5 and also EVOBlue30. In addition, we have used dyes
spread over the full UV-visible excitation wavelength range
using dansyl (excitation maximum = 320 nm), BODIPY FL
(BYFL, 488 nm) and Texas Red (TXR, 590 nm). Furthermore,
we have varied the length of the linker between the active
pharmacophore and ﬂuorophore. Initially, these compounds
were assessed for A1-receptor afﬁnity using whole-cell radioli-
gand binding (
3H-DPCPX) and also for functional potency
and efﬁcacy using a CRE-based reporter gene assay.
Fluorescent XAC derivatives
Whole-cell binding in CHO-A1 cells using
3H-DPCPX con-
ﬁrmed that the afﬁnity of XAC itself was similar to that
previously shown (Table 2; Figure 3). In line with our previous
Fluorescent A1 receptor ligands
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Figure 2 Chemical structures of ﬂuorescent XAC derivatives. AEAO, 8-(2-aminoethylamino)-8-oxooctanoyl; AHH, 6-(6-
aminohexanamido)hexanoyl; AO, 8-aminooctanoyl; X, 6-aminohexanoyl; XAC, xanthine amine congener.
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Compound no. Compound name Parent ligand Mass spectroscopy
1 APrEA-X-BY630 NECA C44H49BF2N10O7S (MH)
+ requires 911.3647, found 911.3718
2 ABEA-X-BY630 NECA C45H51BF2N10O7S (MH)
+ requires 925.3803, found 925.3842
3 APEA-X-BY630 NECA C46H53BF2N10O7S (MH)
+ requires 939.3960, found 939.4054
4 AOEA-X-BY630 NECA C49H60BF2N10O7S (MH)
+ requires 981.4428, found 981.4470
5 ADOEA-X-BY630 NECA C47H56BF2N10O9S (MH)
+ requires 985.4014, found 985.4111
6 ABEA-BYFL NECA C30H39BF2N9O5 (MH)
+ requires 654.3135, found 654.3098
7 ABEA-dansyl NECA C28H37N8O6S (MH)
+ requires 613.2557, found 613.2532
8 ABEA-AO-dansyl NECA C36H52N9O7S (MH)
+ requires 754.3710, found 754.3744
9 ABEA-X-BYFL NECA C36H50BF2N10O6 (MH)
+ requires 767.3976, found 767.3962
10 AUEA-dansyl NECA C35H51N8O6S (MH)
+ requires 711.3652, found 711.3609
11 ABEA-X-Texas Red NECA C53H65N10O11S2 (MH)
+ requires 1081.4270, found 1081.4360
12 ABEA-Cy5 NECA C49H63N9O11S2 (MH)
+ requires 1018.4161, found 1018.4229
13 ABEA-EVOBlue 30 NECA C37H49N10O9S (MH)
+ requires 809.3399, found 809.3427
14 XAC-X-BY630 XAC C50H55BF2N9O7S (MH)
+ requires 974.4006, found 974.4041
15 XAC-X-Texas Red XAC C58H68N9O11S2 (MH)
+ requires 1130.4480, found 1130.4530
16 XAC-Cy5 XAC C54H67N8O11S2 (M2H)
+ requires 1067.4365, found 1067.4495
17 XAC-AEAO-BYFL XAC C45H60BF2N10O7 (MH)
+ requires 901.4708, found 901.4691
18 XAC-EVOBlue 30 XAC C42H52N9O9S (MH)
+ requires 858.3609, found 858.3646
19 XAC-dansyl XAC C33H40N7O6S (MH)
+ requires 662.2761, found 662.2740
20 XAC-AO-dansyl XAC C41H55N8O7S (MH)
+ requires 803.3914, found 803.3971
21 XAC-AHH-dansyl XAC C45H65N9O8S (MH)
+ requires 888.4442, found 888.4612
The conﬁrmed molecular weight from mass spectroscopy is also compared with the predicted molecular weight for the ﬁnal product.
ABEA, N6-(4-aminobutyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; ADOEA, N6-(8-amino-3,6-dioxaoctyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; AEAO,
8-(2-aminoethylamino)-8-oxooctanoyl; AHH, 6-(6-aminohexanamido)hexanoyl (see Figures 1 and 2 for complete structures); AO, 8-aminooctanoyl; AOEA,
N6-(8-aminooctyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; APEA, N6-(5-aminopentyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; APrEA, N6-(3-aminopropyl)-5′-
ethylamino-5′-oxo-5′-deoxyadenosine; AUEA, N6-(11-aminoundecyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; NECA, 5′(N-ethylcarboxamido)adenosine; X,
6-aminohexanoyl; XAC, xanthine amine congener.
Table 2 Inhibition of speciﬁc binding of
3H-DPCPX to the adenosine A1-receptor by ﬂuorescent analogues of NECA and XAC
Log KD
1 Log IC50 % Inhibition
2 n
NECA -5.97  0.03 8
APrEA-X-BY630 -6.62  0.09 (apparent) -6.51  0.10 55.4  2.5% 10
ABEA-X-BY630 -5.93  0.10 (apparent) -5.81  0.10 46.2  4.9% 10
APEA-X-BY630 -6.01  0.25 (apparent) -5.89  0.25 45.3  4.2% 9
AOEA-X-BY630 -6.15  0.21 (apparent) -6.04  0.21 19.7  3.6% 7
ADOEA-X-BY630 -6.19  0.24 (apparent) -6.23  0.23 24.3  4.8% 7
ABEA-dansyl >-45
ABEA-AO-dansyl NI 3
AUEA-dansyl -4.97  0.15 (apparent) -4.83  0.15 44.8  2.3% 6
ABEA-X-Texas Red >-46
ABEA-EVOBlue 30 >-52
ABEA-Cy5 NI 4
ABEA-BYFL NI 4
ABEA-X-BYFL >-45
XAC -7.38  0.05 11
XAC-X-BY630 -7.42  0.05 (apparent) -7.28  0.05 82.3  1.4% 10
XAC-X-Texas Red -5.72  0.07 7
XAC-AEAO-BYFL NI 5
XAC-EVOBlue 30 -5.27  0.11 6
XAC-Cy5 -5.59  0.02 6
XAC-dansyl -6.71  0.05 7
XAC-AO-dansyl -6.91  0.09 (apparent) -6.77  0.09 91.0  0.5% 6
XAC-AHH-dansyl -6.87  0.05 (apparent) -6.73  0.04 81.0  0.9% 6
All values are mean  SEM.
1Unless otherwise stated, KD values were calculated as described under Methods. In those situations where a maximal inhibition of speciﬁc binding was obtained
that was less than 100% (deﬁned with 10 mM XAC), an apparent KD was calculated from the IC50 of the displaceable component of binding.
2Where indicated, maximum inhibition of speciﬁc binding was obtained that was less than that deﬁned with 10 mM XAC.
ABEA, N6-(4-aminobutyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; ADOEA, N6-(8-amino-3,6-dioxaoctyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; AEAO,
8-(2-aminoethylamino)-8-oxooctanoyl; AHH, 6-(6-aminohexanamido)hexanoyl (See Figures 1 and 2 for complete structures); AO, 8-aminooctanoyl; AOEA,
N6-(8-aminooctyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; APEA, N6-(5-aminopentyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; APrEA, N6-(3-aminopropyl)-5′-
ethylamino-5′-oxo-5′-deoxyadenosine; AUEA, N6-(11-aminoundecyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; NECA, 5′(N-ethylcarboxamido)adenosine; NI, no
inhibition of speciﬁc binding at concentrations up to 0.1 mM; X, 6-aminohexanoyl; XAC, xanthine amine congener.
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the adenosine A1 receptor (Table 2), and inhibited over 80% of
speciﬁc binding (Figure 3). Derivatives in which the ﬂuoro-
phore was changed, but which had an equivalent linker
length, showed signiﬁcant differences in their binding prop-
erties (Table 2). XAC-AO-dansyl (20) showed a reduced
but reasonable afﬁnity. In contrast, XAC-Cy5 (16), XAC-
EVOBlue30 (18) and XAC-X-TXR (15) were at least 10-fold
less potent than the BODIPY630/650 derivative. The
BODIPY-FL derivative of XAC (XAC-AEAO-BYFL; 17) showed
no displacement of speciﬁc binding at concentrations up to
10 mM (Figure 3).
The effect of linker length was investigated using three
dansyl derivatives (XAC-dansyl (19), XAC-AO-dansyl (20)
and XAC-AHH-dansyl (21)), with relative chain lengths of 0,
9 and 14 atoms, respectively. Interestingly, increasing the
chain length had no signiﬁcant effect on the binding afﬁnity
of the ligand, but did seem to decrease slightly the maximum
displacement of
3H-DPCPX (Table 2).
The adenosine A1 receptor is primarily a Gi-coupled recep-
tor, and, as such, agonist responses result in a decrease in
cAMP and CRE-mediated gene transcription responses (Baker
and Hill, 2007). In order to make these inhibitory responses
easier to see, forskolin was added to the experiments in order
to raise the basal adenylyl cyclase activity, and thus cAMP and
CRE-gene transcription levels. In the presence of forskolin,
the agonist response to NECA is comprised of both an inhibi-
tory Gi-mediated inhibition of gene transcription and, at
higher agonist concentrations, a Gs-mediated enhancement
of the response to forskolin (Figure 4). We have previously
shown that both the Gi and Gs responses to NECA in this cell
line are mediated via the adenosine A1 receptor (Baker and
Hill, 2007). Inverse agonists, however, result in an increase in
adenylyl cyclase activity and an increase in CRE-mediated
gene transcription (Figure 4; Baker and Hill, 2007). Log KD
values obtained from antagonism of the Gs and Gi phases of
the NECA response for each ﬂuorescent antagonist were very
similar (Table 3). The Gs phase of the NECA response could be
isolated by pretreatment with PTX, and the KD values for
ﬂuorescent antagonists were again similar (Table 3).
All of the ﬂuorescent derivatives of XAC that were able to
antagonize NECA-stimulated Gi-mediated responses, also
acted as inverse agonists (Table 4; Figure 4). Table 4 shows the
mean log EC50 values for an increase in CRE-mediated gene
transcription that are in good agreement with the antagonist
KD values obtained from antagonism of NECA-stimulated
responses (Table 3). Interestingly, similar KD values were
obtained for XAC-X-BY630 (14), XAC-X-TXR (15) and Dansyl
derivatives of XAC (19, 20, 21) from inhibition of DPCPX
binding (Table 2).
Fluorescent NECA derivatives
In whole cell radioligand binding assays, the parent
A1-receptor agonist, NECA, fully inhibited speciﬁc binding
with a log KD value of -5.97 (see Table 2; Figure 3). The pre-
viously characterized A1 receptor agonist ABEA-X-BY630 (2)
had a similar apparent log KD value to NECA (Table 2:
Figure 3), but displaced only 50% of the speciﬁc binding as
previously reported (Middleton et al., 2007). Maintaining a
similar linker length, but altering the ﬂuorophore to Texas
Red (ABEA-X-TR, 11), Cy5 (ABEA-Cy5, 12), EVOBlue30
(ABEA-EVOBlue30, 13) or BODIPY FL (ABEA-X-BYFL, 9) effec-
tively abolished any measurable afﬁnity of the agonists for the
A1 receptor. The dansyl equivalent of ABEA-X-BY630, AUEA-
dansyl (10), did show measurable afﬁnity for the A1 receptor,
but was signiﬁcantly less potent (Table 2).
For the BODIPY 630/650-labelled NECA derivatives, varying
the linker length from three to eight carbon atoms (APrEA-,
ABEA-, APEA- and AOEA-X-BY630, 1,2,3 and 4, respectively)
did not signiﬁcantly change their afﬁnity for the adenosine A1
receptor or their inability to displace all of the speciﬁc
binding. The exception to this was for the longest chain
length, AOEA-X-BY630 (4), which displaced only 20% of the
speciﬁc binding. This lack of displacement was unlikely to be
a solubility issue, as a compound with a diethylene glycol
linker of equivalent length (ADOEA-X-BY630, 5) showed
similar properties. In the case of the dansyl derivatives
varying the carbon chain from 4 carbon atoms in ABEA-
dansyl (7) to 7 carbon atoms in ABEA-AO-dansyl (8), or 11
carbon atoms in AUEA-dansyl (10), indicated that the longer
carbon chain length was required for measurable binding
afﬁnity (Table 2).
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Figure 3 Inhibition of the speciﬁc binding of
3H-DPCPX by ﬂuores-
cent (A) antagonists and (B) agonists in CHO-A1 cells expressing the
human adenosine A1 receptor. Non-speciﬁc binding was deﬁned with
10 mM XAC. 3H-DPCPX was used at (A) 1.30 nM or (B) 1.11 nM.
Values represent mean  SEM from triplicate determinations in a
single experiment. These separate experiments are representative
of (A) ﬁve and (B) seven separate experiments. AEAO, 8-(2-
aminoethylamino)-8-oxooctanoyl; AO, 8-aminooctanoyl; AOEA,
N
6-(8-aminooctyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; APEA, N6-
(5-aminopentyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; APrEA,
N
6-(3-aminopropyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; X, 6-
aminohexanoyl; CHO, Chinese hamster ovary; DPCPX,
8-cyclopentyl-1,3-dipropylxanthine; NECA, 5′ (N-ethylcarboxamido)
adenosine; X, 6-aminohexanoyl; XAC, xanthine amine congener.
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British Journal of Pharmacology (2010) 159 772–786Several of the ﬂuorescent NECA derivatives were also able to
stimulate agonist responses via the adenosine A1 receptor
(Table 5). In each case, the Gi-coupled agonist response was
abolished following pretreatment of the cells with PTX
(Table 5), and could be competitively antagonized by the
non-ﬂuorescent A1 receptor antagonists DPCPX, XAC and
CGS 15943 (Table 6). BODIPY 630/650 derivatives of NECA
were able to stimulate both Gi- and Gs- mediated responses
(Figure 5). However, the increased length of the linker
resulted in lower potency and reduced Gs responses (Figure 5).
The dansyl derivatives of NECA elicited Gi-mediated
responses, but no signiﬁcant activation of Gs-mediated
responses was observed over the concentration range studied
(Table 5; Figure 6). This was probably a consequence of their
lower potency and the inability to reach concentrations at
which a Gs response would be visible.
It was notable that while BODIPY 630/650 derivatives of
NECA became less potent as the carbon chain length
increased, the opposite was true for the dansyl derivatives,
with the most potent compound being AUEA-dansyl (10),
with an 11 carbon linker (Table 5; Figures 5 and 6). This was
in keeping with AUEA-dansyl providing the only measurable
binding afﬁnity in whole cell ligand-binding studies. It was
notable that IC50 values for the Gi-mediated function gene
transcription responses were generally much lower than the
KD values obtained in binding experiments for all agonists.
This reﬂects the fact that this is a well-coupled system and
explains why weak agonist responses were obtained for
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Figure 4 CRE-SPAP production in CHO-A1 cells in response to (A) NECA in the presence and absence of 1 mM XAC-X-BY630 (14); (B) NECA
in the presence and absence of 1 mM XAC-X-Texas Red (XAC-X-TXR; 15); (C) NECA in the presence and absence of 1 mM XAC-AEAO-BYFL (17);
(D) XAC-X-BY630 (14); (E) XAC-X-Texas Red (XAC-X-TXR) and (F) XAC-AEAO-BYFL (17). Bars show basal CRE-SPAP production, that in
response to 3 mM forskolin, and for A–C, that in response to 1 mM of the XAC-derivative in the presence of 3 mM forskolin. Data points are mean
 SEM from triplicate values from a single experiment. These separate experiments are representative of (A) 9, (B) 6, (C) 10, (D) 9, (E) 6 and
(F) 6 separate experiments. AEAO, 8-(2-aminoethylamino)-8-oxooctanoyl; CHO, Chinese hamster ovary; CRE-SPAP, cyclic 3′,5′ adenosine
monophosphate response element-secreted placental alkaline phosphatase; NECA, 5′ (N-ethylcarboxamido)adenosine; X, 6-aminohexanoyl;
XAC, xanthine amine congener.
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3H-DPCPX
binding was detectable. This was particularly true of the
BODIPY FL derivatives ABEA-BYFL (6) and ABEA-X-BYFL (9).
Visualizing ligand binding to live cells
All of the ﬂuorescent ligands were examined under the con-
focal microscope for their ability to bind to CHO-A1 cells
(Figure 7). When XAC-X-TXR (15) was monitored at the
single-cell level, no speciﬁc binding was seen at concentra-
tions up to 30 nM. At 30 nM, bright ﬂuorescence was seen
between cells (Figure 7E), suggesting that enough of the
ﬂuorescent molecules were present to be detected by confocal
microscopy, but this ﬂuorescence was lost immediately on
washout of the label (Figure 7F). In the case of the dansyl
derivatives (both agonist and antagonist), no increase in ﬂuo-
rescence was seen above the level of autoﬂuoresence from the
cells (Figure 7G,H). Furthermore, unlike the situation with
XAC-X-TXR (15), no dansyl ﬂuorescence was detected in solu-
tion. When XAC-X-BY630 (14) and the BODIPY 630/650
derivatives of NECA (1–4) were visualized, clear membrane
binding was observed even in the continued presence of ﬂuo-
rescentligand(Figure 7A–D).Thislatterresultsuggeststhatthe
BODIPY 630/650 ﬂuorophore is heavily quenched in aqueous
solution. This suggestion was reinforced when excitation and
emission spectra for XAC-dansyl (19), XAC-X-TR (15) and
XAC-X-BY630 (14) were determined in HBS and methanol
(Figure 8). The ratio of peak emission intensities in HBS com-
pared with methanol was 0.89 for XAC-X-TR (15), 0.26 for
XAC-dansyl (19) and 0.07 for XAC-X-BY630 (14). It was also
notable that clear membrane binding could be detected with
XAC-X-BY630 when confocal imaging was undertaken in
the presence of Brilliant Black BN (50 mM), which heavily
quenches the extracellular aqueous ﬂuorescence (Figure 9).
Discussion
XAC and its antagonist ﬂuorescent derivatives
XAC is a well-known antagonist of the human adenosine A1
receptor. It bound with high afﬁnity to the human adenosine
A1 receptor in this transfected cell system (log KD -7.38). In
keeping with previous ﬁndings, the inverse agonist nature of
this ligand was also evident (Baker and Hill, 2007). The addi-
tion of EVOBlue30, Cy5 and BODIPY-FL ﬂuorophores to XAC
resulted in a large loss in afﬁnity of the resultant molecules,
with only very weak binding being detected for XAC-Cy5 (16)
and XAC-EVOBlue30 (18). None of these XAC derivatives
were able to inhibit any of the NECA agonist responses (at a
concentration up to 1 mM for the ﬂuorescent XAC ligand).
The addition of the EVOBlue, Cy5 and BODIPY-FL ﬂuoro-
phores to XAC therefore resulted in a loss of pharmacological
activity of the XAC molecule that was due to a large reduction
in afﬁnity for the adenosine A1 receptor.
When the XAC-X-Texas Red (15) molecule was examined,
the afﬁnity as measured by
3H-DPCPX binding was about
30-fold lower than that seen with the parent XAC. XAC-X-
Texas Red (15) was also able to inhibit the NECA agonist
responses, and this included both those occurring via the
Gi-and Gs-coupled states of the receptor (Table 3). However,
when XAC-X-Texas Red (15) was monitored at the single-cell
level, no speciﬁc binding was seen at concentrations up to
30 nM. At 30 nM, bright ﬂuorescence was seen between cells,
suggesting that enough ﬂuorescent molecules were present to
be detected by confocal microscopy, but this ﬂuorescence was
lost immediately on washout of the label. This suggests that
the afﬁnity of XAC-X-Texas Red (15) for the adenosine A1
receptor is too low for successful imaging studies.
The addition of the smaller dansyl ﬂuorophore to XAC
resulted in a molecule that maintained high afﬁnity at the A1
Table 3 Log KD values from antagonism of NECA-mediated inhibition (Gi) and enhancement (Gs) of forskolin-stimulated CRE reporter
gene responses
Antagonist Log KD n Log KD n +PTX n
Gi Gs Gs
XAC -7.86  0.05 14 -7.92  0.04 14 -7.99  0.05 6
XAC-X-BY630 -6.92  0.09 9 -6.94  0.06 12 -7.14  0.05 6
XAC-X-Texas Red -6.00  0.15 6 -6.09  0.08 7 -6.31  0.10 4
XAC-dansyl -7.37  0.08 8 -7.31  0.03 7 -7.22  0.17 7
XAC-AO-dansyl -7.43  0.07 6 -7.42  0.09 6 -7.02  0.10 6
XAC-AHH-dansyl -7.14  0.15 5 -7.30  0.10 5 -6.99  0.09 6
Values represent mean  SEM of n separate experiments. KD values were determined from the parallel shifts obtained in the inhibitory (Gi) and stimulatory (Gs)
phases of the NECA concentration response curves. In some experiments (+PTX), cells were incubated overnight with PTX (100 ng·mL–1), and under these
conditions, only a stimulatory response (Gs) was obtained. No antagonism was seen with XAC-AEAO-BYFL, XAC-EVOBlue 30 or XAC-Cy5 at concentrations up to
1 mM.
AEAO, 8-(2-aminoethylamino)-8-oxooctanoyl; AO, 8-aminooctanoyl; CRE, cyclic AMP response element; NECA, 5′(N-ethylcarboxamido)adenosine; PTX, Pertussis
toxin; X, 6-aminohexanoyl; XAC, xanthine amine congener.
Table 4 Inverse agonist effects of ﬂuorescent XAC derivatives
Antagonist (log EC50) n Fold increase
XAC -7.15  0.14 9 1.41  0.07
XAC-X-BY630 -6.93  0.12 9 1.32  0.04
XAC-X-Texas Red -5.82  0.22 6 1.26  0.06
XAC-dansyl -6.84  0.16 9 1.47  0.08
XAC-AO-dansyl -7.52  0.17 7 1.20  0.03
XAC-AHH-dansyl -6.80  0.14 5 1.40  0.10
Values represent mean  SEM of n separate experiments.
AHH, 6-(6-aminohexanamido)hexanoyl (see Figures 1 and 2 for complete
structures); AO, 8-aminooctanoyl; X, 6-aminohexanoyl; XAC, xanthine amine
congener.
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This was true whether the afﬁnity was deduced from inhibi-
tion of speciﬁc
3H-DPCPX binding or from inhibition of the
NECA-stimulated reporter gene responses (Tables 2 and 3).
The addition of the dansyl ﬂuorophore therefore had little
effect on the pharmacological properties of XAC. However,
when the ligands were visualized, no binding was seen at all.
In fact, no increase in ﬂuorescence was seen above the level of
cellular autoﬂuoresence (Figure 7). Furthermore, unlike the
situation with XAC-X-Texas Red (15), no dansyl ﬂuorescence
was detected in solution. This is consistent with the relatively
weak ﬂuorescence intensity normally observed with dansyl
ﬂuorophores in aqueous solution (Hayashida et al., 2007).
This ﬂuorophore has been observed previously to demon-
strate sensitivity to the microenvironment polarity such that
its ﬂuorescence intensity increases in lower polarity environ-
ments along with a blue shift in emission wavelength
(Hayashida et al., 2007). The increase in ﬂuorescence intensity
in environments of lower polarity (methanol) was also dem-
onstrated directly in the present study (Figure 8), although
the emission wavelength increased slightly. These data
suggest that when the dansyl derivatives are bound to the
adenosine A1 receptor, the ﬂuorophore is likely to be located
within an aqueous and/or highly quenched environment.
The addition of BODIPY 630/650 ﬂuorophore to the XAC
molecule made no difference to the afﬁnity of the molecules
as determined from
3H-DPCPX whole cell binding. The
inverse agonist activity of the molecule was maintained, as
was the afﬁnity when measured at both the Gi- and
Gs-coupled states of the receptor. Furthermore, when XAC-X-
BY630 (14) was visualized using the confocal microscope,
clear membrane binding was observed, which remained even
Table 5 Agonist responses to ﬂuorescent NECA analogues at the adenosine A1 receptor
Agonist Gi (log IC50) n Gs (log EC50) n +PTX
Gs (log EC50)G s EMAX (fold increase) n Log KD - Log IC50
NECA -8.43  0.04 15 -6.13  0.03 15 -6.37  0.04 1.81  0.07 13 1.92
APrEA-X-BY630 -8.21  0.11 8 -6.18  0.13 8 -6.62  0.13 1.67  0.06 7 2.40
ABEA-X-BY630 -7.92  0.06 8 -6.38  0.17 6 -6.40  0.06 1.44  0.03 8 2.03
APEA-X-BY630 -7.97  0.07 8 -6.23  0.13 5 -6.58  0.06 1.41  0.06 11 1.93
AOEA-X-BY630 -7.32  0.09 6 NS >-5 1.28
ADOEA-X-BY630 -7.20  0.17 6 -5.79  0.11 4 -5.97  0.07 1.31  0.06 4 0.97
ABEA-dansyl -5.95  0.09 7 NS >-57
ABEA-AO-dansyl -6.64  0.08 10 NS >-67
AUEA-dansyl -7.08  0.08 8 NS NS 7 2.25
ABEA-X-Texas Red -6.05  0.17 3 NS 3 NS 3
ABEA-EVOBlue 30 -5.45  0.11 3 NS 3 NS 3
ABEA-Cy5 -5.27  0.35 3 NS 3 NS 3
ABEA-BYFL -6.03  0.09 7 NS 7 NS 7
ABEA-X-BYFL -6.57  0.08 7 NS 7 >-57
Values represent mean  SEM of n separate experiments. Values are log (IC50) and log (EC50) determinations from the agonist-mediated inhibition (Gi)o r
enhancement (Gs), respectively, of forskolin-stimulated CRE-reporter gene activity. In some experiments (+PTX), cells were incubated overnight with PTX
(100 ng·mL-1), and under these conditions, only a stimulatory response (Gs) was obtained. An indication of agonist efﬁcacy is provided by the difference between
log IC50 values and the log KD values reported for each agonist in Table 2.
ABEA, N6-(4-aminobutyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; ADOEA, N6-(8-amino-3,6-dioxaoctyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; AEAO,
8-(2-aminoethylamino)-8-oxooctanoyl; AO, 8-aminooctanoyl; AOEA, N6-(8-aminooctyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; APEA, N6-(5-aminopentyl)-
5′-ethylamino-5′-oxo-5′-deoxyadenosine; APrEA, N6-(3-aminopropyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; AUEA, N6-(11-aminoundecyl)-5′-ethylamino-5′-
oxo-5′-deoxyadenosine; PTX, Pertussis toxin; NECA, adenosine-5′-N-ethyluronamide; NS, no stimulation; X, 6-aminohexanoyl.
Table 6 Antagonism of ﬂuorescent agonist Gi-mediated responses by DPCPX, XAC and CGS15943
Agonist log KD DPCPX n tog KD XAC n log KD CGS n
NECA -9.13  0.10 7 -7.86  0.05 14 -8.80  0.10 3
APrEA-X-BY630 -8.70  0.09 8 -7.62  0.07 7 -8.58  0.12 7
ABEA-X-BY630 -8.69  0.06 8 -7.55  0.08 8 -8.54  0.09 8
APEA-X-BY630 -8.61  0.06 8 -7.56  0.08 8 -8.57  0.10 8
AOEA-X-BY630 -8.97  0.07 3 -7.87  0.09 3 -8.87  0.15 3
ADOEA-X-BY630 -8.67  0.09 6 -7.71  0.07 6 -8.67  0.08 6
ABEA-dansyl -8.76  0.06 6 -7.90  0.06 6 -8.78  0.07 6
ABEA-AO-dansyl -8.78  0.15 5 -7.74  0.12 5 -8.90  0.19 6
AUEA-dansyl -8.80  0.12 7 -7.97  0.10 6 -8.96  0.11 7
ABEA-X-BYFL -8.73  0.16 5 -7.83  0.13 5 -8.69  0.15 6
Values represent mean  SEM from n separate experiments.
ABEA, N6-(4-aminobutyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; ADOEA, N6-(8-amino-3,6-dioxaoctyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; AO,
8-aminooctanoyl; AOEA, N6-(8-aminooctyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; APEA, N6-(5-aminopentyl)- 5′-ethylamino-5′-oxo-5′-deoxyadenosine; APrEA,
N6-(3-aminopropyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; AUEA, N6-(11-aminoundecyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; CGS 15943, 5-amino-9-
chloro-2-(2-furyl)1,2,4-trizolo[1,5-c]quinazoline; DPCPX, 8-cyclopentyl-1,3-dipropylxanthine; NECA, 5′(N-ethylcarboxamido)adenosine; X, 6-aminohexanoyl;
XAC, xanthine amine congener.
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Thus, the addition of BODIPY 630/650 to XAC had very little
effect on the pharmacology of the molecule, with all the
pharmacological properties being preserved in addition to
good ﬂuorescent properties. A striking property of the
BODIPY 630/650 ligands was that membrane binding to cells
expressing the adenosine A1 receptor could be determined in
the continued presence of the ﬂuorescent ligand. These data
suggest that the ﬂuorescence intensity of the BODIPY 630/650
ﬂuorophore increases on binding to the receptor. Thus, unlike
the dansyl congeners, the BODIPY 630/650 ﬂuorophore is
likely to be located within a non-polar environment when
bound to the A1 receptor.
NECA and its ﬂuorescent derivatives
NECA had a binding afﬁnity as measured by
3H-DPCPX
whole-cell binding of 1 mM. The IC50 for activation of the
adenosine A1 receptor was, however, 38 nM. This is because
NECA is a highly efﬁcacious agonist and needs to occupy only
a few receptors to stimulate a full agonist response. This
highly efﬁcacious nature of NECA makes it an ideal choice for
the starting molecule from which to make ﬂuorescent deriva-
tives. Adenosine A1 receptors have also been shown to couple
to Gs-coupled receptors in CHO cells (Cordeaux et al., 2000;
2004; Baker and Hill, 2007), and the EC50 for stimulation by
NECA of the Gs-coupled state of the receptor (794 nM) shows
that this coupling is much less efﬁcient.
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Figure 5 CRE-SPAP production in CHO-A1 cells in response to APrEA-X-BY630 (A and D), APEA-X-BY630 (B and E), ADOEA-X-BY630 (C and
F) in the presence and absence of 30 nM DPCPX (A, B and C) and 10 nM DPCPX (D, E and F). The cells in D, E and F were incubated with
PTX (100 ng·mL-1) for 24 h before experimentation. Bars show basal CRE-SPAP production, that in response to 3 mM forskolin and that in
response to either 30 nM or 10 nM DPCPX in the presence of 3 mM forskolin. Data points are mean  SEM from triplicate values from a single
experiment. These separate experiments are representative of (A) 8, (B) 8, (C) 6, (D) 6, (E) 6 and (F) 6 separate experiments. ADOEA,
N
6-(8-amino-3,6-dioxaoctyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; APEA, N6-(5-aminopentyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine;
APrEA, N6-(3-aminopropyl)-5′-ethylamino-5′-oxo-5′-deoxyadenosine; CHO, Chinese hamster ovary; CRE-SPAP, cyclic AMP response element-
secreted placental alkaline phosphatase; DPCPX, 8-cyclopentyl-1,3-dipropylxanthine; NECA, 5′ (N-ethylcarboxamido)adenosine; PTX, Pertussis
toxin; X, 6-aminohexanoyl.
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ﬂuorescent adenosine A1 receptor antagonists to give values
similar to those previously published (Baker and Hill, 2007).
The afﬁnity of non-ﬂuorescent antagonists was the same for
both the NECA–Gi-induced state of the receptor, and the
NECA-induced Gs state of the receptor. The Gs-coupled state
could be isolated by pre-incubating the cells with PTX. This
resulted in a complete abolition of the inhibitory Gi-response
(i.e. the reduction in CRE-gene transcription), leaving only
the Gs-stimulatory response intact. The afﬁnity of the non-
ﬂuorescent antagonists measured under these conditions was
also identical.
The addition of the EVOBlue30, Texas Red and Cy5 ﬂuoro-
phores to the parent NECA molecule completely abolished all
measurable pharmacological activity. The addition of the
BODIPY-FL ﬂuorophore resulted in molecules with much
reduced potency, which was probably due to a reduction in
afﬁnity, as no binding was detectable. The agonist response to
these molecules was mediated by the adenosine A1 receptor, as
it could be inhibited by non-ﬂuorescent A1 receptor antago-
nists to give the same afﬁnity (log KD values) as for the parent
NECA. Furthermore, the response was abolished following
PTX pretreatment conﬁrming that it was occurring via the
Gi-coupled state of the receptor. However, when these NECA
derivatives were examined using confocal microscopy, no spe-
ciﬁc binding was seen with any of the ligands. Thus, although
ABEA-X-BYFL (9) had marginal functional activity, none of
the Texas Red, EVOblue30, Cy5 or BODIPY-FL derivatives
have useful functional or ﬂuorescent use.
The addition of the dansyl derivatives to the parent NECA
molecule did result in functionally active molecules. These
molecules had reduced afﬁnity for the adenosine A1 receptor
(Table 2); however agonist Gi-coupled inhibitory functional
responses were still seen. Although none of the dansyl deriva-
tives of NECA were sufﬁciently efﬁcacious to induce the
Gs-coupled state of the A1 receptor, it is interesting to note
that lengthening the carbon chain in the linker between the
NECA moiety and ﬂuorophore from C4 to C11 (AUEA-dansyl,
10) resulted in an increase in agonist potency of 10-fold, and
that this was most likely due to an increase in afﬁnity
(Table 2). However, the combination of lower afﬁnity for the
adenosine A1 receptor, together with the problems high-
lighted above for dansyl XAC derivatives regarding the low
ﬂuorescence intensity of the dansyl ﬂuorophore in polar
aqueous environments, is the most likely explanation of the
lack of success with these ligands in confocal microscopy
studies.
The addition of a BODIPY 630/650 ﬂuorophore resulted in
a series of functionally active molecules. It was only possible
to determine the apparent afﬁnity (log KD values) of the
ﬂuorescent NECA BODIPY 630/650 derivatives from the
0.75
1.00
Basal
Forskolin 3μM
AUEA-dansyl
t
s
)
0.00
0.25
0.50
ABEA-AO-dansyl
ABEA-dansyl
S
P
A
P
 
p
r
o
d
u
c
t
i
o
n
(
O
D
 
u
n
i
–12 –11 –10 –9 –8 –7 –6 –5
            log[NECA-dansyl-derivative](M)
Figure 6 CRE-SPAP production in CHO-A1 cells in response to
NECA-dansyl derivatives (AUEA-dansyl, ABEA-AO-dansyl and ABEA-
dansyl). Bars show basal CRE-SPAP production, that in response to
3 mM forskolin. Data points are mean  SEM from triplicate values
from a single experiment and this is representative of seven separate
experiments. ABEA, N
6-(4-aminobutyl)-5′-ethylamino-5′-oxo-5′-
deoxyadenosine; AUEA, N
6-(11-aminoundecyl)-5′-ethylamino-5′-
oxo-5′-deoxyadenosine; CHO, Chinese hamster ovary; CRE-SPAP,
cyclic AMP response element-secreted placental alkaline phos-
phatase; NECA, 5′ (N-ethylcarboxamido)adenosine.
A B
CD
EF
G H
Figure 7 Confocal images of CHO-A1 cells incubated (5 min) with:
(A) APrEA-X-BY630 (10 nM), (B) ADOEA-X-BY630 (10 nM), (C, D)
XAC-X-BY630 (30 nM), (E, F) XAC-X-Texas Red (30 nM) and (G)
XAC-dansyl (10 nM). In D and F, images were collected immediately
after the ﬂuorescent ligand had been removed from the cells. H
shows a representative image of autoﬂuorescence collected under
identical conditions to image (G), but without the addition of
XAC-dansyl. ADOEA, N
6-(8-amino-3,6-dioxaoctyl)-5′-ethylamino-5′-
oxo-5′-deoxyadenosine; APrEA, N6-(3-aminopropyl)-5′-ethylamino-
5′-oxo-5′-deoxyadenosine; CHO, Chinese hamster ovary; X,
6-aminohexanoyl; XAC, xanthine amine congener.
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ﬂuorescent analogues did not inhibit all of the speciﬁc
binding. We have observed this previously for the ABEA-X-
BY630 (2) derivative (Middleton et al., 2007), and shown that
this may be partly due to differential penetration of the ﬂuo-
rescent ligand and
3H-DPCPX into the intracellular environ-
ment of intact cells. Thus, permeabilization of cells did
increase the percentage of speciﬁc binding inhibited by this
ﬂuorescent agonist by allowing access to intracellular
receptors (Middleton et al., 2007). An alternative interpreta-
tion is that these ﬂuorescent analogues are acting allosteri-
cally to inhibit binding of
3H-DPCPX (Christopolous and
Kenakin, 2002; Kenakin, 2004; May et al., 2007).
It is interesting, however, to note that the log IC50 values of
the BODIPY 630/650 derivatives in the functional Gi protein-
coupled CRE response increased as the linker lengthened. This
did not appear to be due to a decrease in binding afﬁnity
(Table 2), but rather reﬂected a decrease in agonist efﬁcacy. If
one takes the difference between log IC50 and apparent log KD
values as a measure of efﬁcacy, then there was a clear decrease
in efﬁcacy as the chain length increased (Table 5). All but
AOEA-X-BY630 (4) were able to stimulate an increase in CRE-
gene transcription by inducing a Gs-coupled state of the
adenosine A1 receptor at higher concentrations. Interestingly,
the ADOEA-X-BY630 (5) analogue was equally potent with
AOEA-X-BY630 (which has an identical linker length) at
inhibiting CRE-gene transcription, but retained some
Gs-stimulating activity (Table 5). These data suggest that the
latter compound has a reduced afﬁnity and/or efﬁcacy for the
Gs-coupled conformation of the adenosine A1 receptor com-
pared with the other ﬂuorescent agonists.
In the case of the dansyl NECA derivatives, there is a hint
that afﬁnity and/or efﬁcacy increases as the chain length
increases. This is opposite to the ﬁnding with the BODIPY
630/650 derivatives, and this observation may provide a
clue to the orientation of the ﬂuorophore within the
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Figure 8 Normalized excitation and emission spectra obtained in
HBS or methanol for (A) XAC-dansyl (50 mM), (B) XAC-X-Texas Red
(1 mM) and (C) XAC-X-BY630 (1 mM). Data have been normalized to
the maximum excitation or emission obtained with each ligand in
methanol. Excitation maxima were: (A) 320, 315 nm; (B) 590,
585 nm and (C) 628, 634 nm in HBS and methanol respectively.
Corresponding emission maxima were: (A) 500, 525 nm; (B) 605,
600 nm and (C) 645, 640 nm. The relative maximal emission inten-
sities (HBS; methanol) were: (A) 0.26; (B) 0.89 and (C) 0.07. HBS,
N-2-Hydroxyethylpiperazine-N′-2-ethanesulfonic acid-buffered sal-
ine; X, 6-aminohexanoyl; XAC, xanthine amine congener.
Control Brilliant Black (50mM)
A B
XAC-X-BY630
(10 nM, 2 min)
C D
Phase
Figure 9 The effect of Brilliant Black on the ﬂuorescence of XAC-X-
BY630 bound to CHO-A1 cells. CHO-A1 cells were incubated with
XAC-X-BY630 (10 nM, 37°C) for 2 min, and a single confocal (A) and
simultaneous phase image (C) were acquired. Immediately following
the addition of the ﬂuorescence quencher, Brilliant Black (50 mM),
similar confocal (B) and phase contrast (D) images were taken, with
the darkening of the phase image indicating a successful addition of
the Brilliant Black. CHO, Chinese hamster ovary; X, 6-aminohexanoyl;
XAC, xanthine amine congener.
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British Journal of Pharmacology (2010) 159 772–786receptor-binding pocket. A comparison of the afﬁnity of XAC-
X-BY630 with all three XAC dansyl derivatives suggests that
binding afﬁnity is retained with both ﬂuorophores. However,
the marked differences in ﬂuorescence intensity of ligand
binding at the single-cell level with these ﬂuorescent ligands
suggest that the dansyl ﬂuorophore is located within an
aqueous environment, whereas the BODIPY 630/650 ﬂuoro-
phore is within a less polar membrane environment. This
suggestion is supported by the data obtained with XAC-dansyl
(19) and XAC-X-BY630 (14) in aqueous buffer or methanol
(Figure 7), which shows a marked quenching of both agents in
aqueous environments. The clear imaging of membrane bind-
ingofXAC-X-BY630(Figure 9)inCHO-A1cellsinthepresence
of Brilliant Black is also consistent with this conclusion.
The opposite inﬂuence of chain length on agonist activity
of the dansyl and BODIPY 630/650 NECA derivatives is
entirely consistent with this interpretation. That is, the
BODIPY 630/650 ﬂuorophore could potentially be placed
within the transmembrane lipid environment of the A1 recep-
tor binding site without interfering with agonist action even
with short linker lengths, whereas the dansyl ﬂuorophore
may alternatively need to exit the binding pocket into the
extracellular aqueous medium on a long linker to avoid
unfavourable interactions with either the surrounding lipid
environment or the receptor itself.
In summary, the present study adds further weight to the
argument that design of a ﬂuorescent ligand needs to take
into account the inﬂuence of both the ﬂuorophore and the
associated linker on the pharmacology of the ﬁnal product.
Furthermore, our data strongly suggest that the physico-
chemical properties of the ﬂuorophore/linker pairing ulti-
mately determine where in the environment of the target
receptor the ﬂuorophore is located, and this, together with
the environmental sensitivity of the resulting ﬂuorescence,
may ultimately decide its utility as a ﬂuorescent probe.
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